Recombinant human endostatin adenovirus
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Recombinant human endostatin adenovirus, covering 2014-11-05 to 2014-11-05. Get the full timeline:
Most recent: Clinical Trial Update: Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors [Phase 2]